WO2010131916A2 - siRNA 접합체 및 그 제조방법 - Google Patents
siRNA 접합체 및 그 제조방법 Download PDFInfo
- Publication number
- WO2010131916A2 WO2010131916A2 PCT/KR2010/003039 KR2010003039W WO2010131916A2 WO 2010131916 A2 WO2010131916 A2 WO 2010131916A2 KR 2010003039 W KR2010003039 W KR 2010003039W WO 2010131916 A2 WO2010131916 A2 WO 2010131916A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sirna
- polymer compound
- conjugate
- formula
- compound
- Prior art date
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 225
- 238000002360 preparation method Methods 0.000 title abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 99
- 238000000034 method Methods 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims description 174
- 229920001223 polyethylene glycol Polymers 0.000 claims description 96
- 239000002202 Polyethylene glycol Substances 0.000 claims description 67
- 239000002105 nanoparticle Substances 0.000 claims description 55
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 229920001600 hydrophobic polymer Polymers 0.000 claims description 30
- 239000007787 solid Substances 0.000 claims description 24
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 19
- -1 4-monomethoxytrityl group Chemical group 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000000304 alkynyl group Chemical group 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 238000001415 gene therapy Methods 0.000 claims description 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 4
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims description 4
- JBWYRBLDOOOJEU-UHFFFAOYSA-N 1-[chloro-(4-methoxyphenyl)-phenylmethyl]-4-methoxybenzene Chemical compound C1=CC(OC)=CC=C1C(Cl)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 JBWYRBLDOOOJEU-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 125000002103 4,4'-dimethoxytriphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)(C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H])C1=C([H])C([H])=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229920000765 poly(2-oxazolines) Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000004055 small Interfering RNA Substances 0.000 description 202
- 108010002687 Survivin Proteins 0.000 description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 38
- 230000014509 gene expression Effects 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 108020004999 messenger RNA Proteins 0.000 description 32
- 102000000763 Survivin Human genes 0.000 description 30
- 239000002299 complementary DNA Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 230000000692 anti-sense effect Effects 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 238000001890 transfection Methods 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 16
- 230000009368 gene silencing by RNA Effects 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 101150055682 HK gene Proteins 0.000 description 11
- 239000012124 Opti-MEM Substances 0.000 description 11
- 239000005289 controlled pore glass Substances 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 108091030071 RNAI Proteins 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 229940126062 Compound A Drugs 0.000 description 8
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 7
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 7
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- 238000010802 RNA extraction kit Methods 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 6
- 238000004445 quantitative analysis Methods 0.000 description 6
- 239000001384 succinic acid Substances 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101000988834 Homo sapiens Hypoxanthine-guanine phosphoribosyltransferase Proteins 0.000 description 5
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 5
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 5
- 102100037935 Polyubiquitin-C Human genes 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
- 108010056354 Ubiquitin C Proteins 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 3
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 3
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 3
- 0 CCOCC*(C)*C(c1ccccc1)(c(cc1)ccc1OC)c(cc1)ccc1OC Chemical compound CCOCC*(C)*C(c1ccccc1)(c(cc1)ccc1OC)c(cc1)ccc1OC 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000693 micelle Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000011191 terminal modification Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical group O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 2
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000004271 Tryptophan 5-monooxygenases Human genes 0.000 description 2
- 108090000885 Tryptophan 5-monooxygenases Proteins 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001476 gene delivery Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- HGBMGRXIQJGDDO-UHFFFAOYSA-N 2-(4-nitrophenyl)butanedioic acid Chemical compound OC(=O)CC(C(O)=O)C1=CC=C([N+]([O-])=O)C=C1 HGBMGRXIQJGDDO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- KMEMIMRPZGDOMG-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid Chemical compound NP(O)OCCC#N KMEMIMRPZGDOMG-UHFFFAOYSA-N 0.000 description 1
- ZGUJFNDDFATBOZ-UHFFFAOYSA-N 2-cyanoethoxyphosphonamidous acid (2-cyanoethylamino)phosphonous acid Chemical compound C(#N)CCNP(O)O.C(#N)CCOP(O)N ZGUJFNDDFATBOZ-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- KYEACNNYFNZCST-UHFFFAOYSA-N CN(C(CC1)=O)C1=O Chemical compound CN(C(CC1)=O)C1=O KYEACNNYFNZCST-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000038018 age-related macular disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- PRYZSLKPMFOUNL-MHIBGBBJSA-N bevasiranib Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2CO)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C(NC(=O)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=NC=NC(N)=C3N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 PRYZSLKPMFOUNL-MHIBGBBJSA-N 0.000 description 1
- 229950006615 bevasiranib Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000000733 zeta-potential measurement Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
- C07F7/0836—Compounds with one or more Si-OH or Si-O-metal linkage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
- C08G65/3356—Polymers modified by chemical after-treatment with organic compounds containing phosphorus having nitrogen in addition to phosphorus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
Definitions
- the present invention provides a conjugate in which a polymer compound that enhances the delivery of siRNA, which can be usefully used for the treatment of cancer and other infectious genes, is conjugated to siRNA using degradable or non-degradable bonds, a method for preparing the conjugate, and siRNA delivery using the conjugate. It is about a method.
- RNA interference is a mechanism that regulates gene expression after nucleotide sequence specificity by double-stranded RNA (dsRNA) in the expression process of genes, such as C. elegans was first discovered plants, fruit flies, mammals Common to animals (Fire et al ., Nature, 391: 806-811, 1998; Novina & Sharp, Nature, 430: 161-164, 2004).
- RNA interference occurs when 19-25bp of dsRNA enters the cell and binds to the RNA-induced silencing complex (RISC) complex, and only the antisense (guide) strand is complementary to the mRNA and is present in the RISC complex.
- RISC RNA-induced silencing complex
- the dsRNA When the dsRNA is delivered intracellularly, the dsRNA binds specifically to the target mRNA sequence and degrades the mRNA. Thus, the dsRNA is considered to be a new tool that can control the expression of genes using the same.
- the introduction of dsRNA into cells caused antiviral interferon pathways, making it difficult to see RNA interference effects.In 2001, Elbashir and Tuschl et al.
- siRNAs have recently been shown to have an excellent effect on inhibiting the expression of specific genes in animal cells, and have attracted much attention as gene therapy agents. Due to their high activity and precise gene selectivity, siRNA oligonucleotides have been studied for the past 20 years and are currently used as therapeutic agents. (ODN) is expected to be a therapeutic replacement (Dana J. Gary et al. Journal of Controlled Release 121: 64-73, 2007).
- ODN is expected to be a therapeutic replacement
- siRNA techniques have a great advantage because they can be easily designed, compared with other pharmaceutical products, and have high target selectivity and characteristics that inhibit the expression of specific genes.
- the inhibition of gene expression by RNA interference is low toxicity because it uses a mechanism that exists naturally in vivo.
- 'Bevasiranib' is an siRNA that inhibits the expression of VEGF by selectively acting on vascular endotherial growth factor (VEGF) that causes angiogenesis.
- VEGF vascular endotherial growth factor
- disease therapies including siRNAs targeting various genes are currently under development (Ryan P. Million, Nature Reviews Drug Discovery 7: 115-116, 2008).
- siRNA delivery requires the use of enzymes in the blood, interactions with elements in the blood and nonspecific delivery to cells. There are many problems that need to be solved (Shigeru Kawakami and Mitsuru Hashida, Drug Metab. Pharmacokinet. 22 (3): 142-151, 2007). Attempts are being made to overcome these problems, in part by using nuclease resistant analogs or by improving delivery techniques.
- gene delivery techniques using viruses such as adenovirus and retroviruses
- gene delivery techniques using non-viral vectors using liposomes, cationic lipids and cationic polymer compounds have been developed.
- viral carriers have a safety problem because the delivered genes cannot enter the host chromosome to induce abnormalities in the host genes or to activate oncogenic genes. Expression may cause autoimmunity, or a modified form of viral infection from the virus carrier may not result in efficient protective immunity.
- Non-viral carriers are less efficient than viral carriers, but have the advantages of low side effects and low production costs, given the safety and economical efficiency in vivo (Lehrman S. Nature. 401 (6753): 517-). 518, 1999).
- RNA molecules including siRNAs, one of which encodes shRNA (short hairpin RNA).
- siRNAs short hairpin RNA
- DNA expression plasmids the system through DNA has the advantage that siRNA is expressed only while the expression vector is present.
- recent studies on chemically modifying siRNAs have suggested methods to improve instability and low cellular uptake of nucleic acids (Shigery Kawakami and Mitsuru Hashida.Drug Metab. Parmacokinet. 22 (3): 142-151). , 2007).
- nucleic Acid Res. 31: 589-595, 2003 Another form of chemical modification is to link the functional groups to the 3 'end of the sense (anti-guide) strand to give enhanced pharmacokinetic characteristics compared to the control and to apply in vivo through the hydrophilic / hydrophobic balance of siRNA. It was found that high efficiency can be induced (Soutschek J. et al . Nature 432: 173-178. 2004).
- the present inventors have found that a conjugate in which a hydrophilic or hydrophobic polymer compound is conjugated to an siRNA using degradable or non-degradable bonds improves the in vivo stability of the siRNA, and completed the present invention.
- An object of the present invention is to conjugate a hydrophilic polymer or hydrophobic polymer compound, which is a biocompatible polymer compound, to a terminal of a sense strand or an antisense strand of a siRNA by using degradable or non-degradable bonds to improve the intracellular delivery efficiency of siRNA.
- Another object of the present invention is a solid support comprising a polymer compound, in particular a polymer compound having proven stability in human application, such as polyethylene glycol (PEG), and RNA, DNA, wherein PEG is bonded to 3 'using the support. It is to provide a method for efficiently preparing oligonucleotides comprising RNA-DNA chimera and analogues.
- a polymer compound in particular a polymer compound having proven stability in human application, such as polyethylene glycol (PEG), and RNA, DNA, wherein PEG is bonded to 3 'using the support.
- Another object of the present invention is to provide a method for preparing the siRNA conjugate and a method for delivering siRNA using the siRNA conjugate.
- a first aspect of the present invention for achieving the above object provides a siRNA and a polymer compound conjugate of the following structure:
- a and B are each independently a hydrophilic polymer or a hydrophobic polymer compound, X, Y are each independently a simple covalent bond or a linker-mediated covalent bond, R represents siRNA.
- a second aspect of the present invention provides a siRNA and a polymer compound conjugate having the structure:
- A is a hydrophobic polymer compound
- X is a simple covalent bond or a linker-mediated covalent bond
- R represents siRNA.
- the third aspect of the present invention also provides a conjugate in which the single strand of the siRNA (R) is composed of 19 to 31 nucleotides.
- the fourth aspect of the present invention provides a conjugate, wherein the hydrophobic polymer compound (A) is a hydrophobic polymer compound having a molecular weight of 250 to 1,000.
- the fifth aspect of the present invention provides a conjugate wherein the hydrophobic polymer compound (A) is C 16 -C 50 saturated hydrocarbon or cholesterol.
- the sixth aspect of the present invention also provides a conjugate wherein the covalent bond (X, Y) is a non-degradable bond or a degradable bond.
- the seventh aspect of the present invention also provides a conjugate wherein the non-degradable bond is an amide bond or a phosphate bond.
- the eighth aspect of the present invention provides a conjugate wherein the degradable bond is selected from disulfide bonds, acid decomposable bonds, ester bonds, anhydride bonds, biodegradable bonds, and enzyme degradable bonds.
- the ninth aspect of the present invention also provides a conjugate in which the hydrophilic polymer compound (A or B) is a nonionic polymer compound having a molecular weight of 1,000 to 10,000.
- the tenth aspect of the present invention also provides a conjugate wherein the hydrophilic polymer compound is selected from the group consisting of polyethylene glycol, polyvinylpyrrolidone, and polyoxazoline.
- the eleventh aspect of the present invention also provides a solid support having a polyethylene glycol having the structure:
- R is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl or heteroaryl; m is an integer from 2 to 18 and n is an integer from 5 to 120; X is hydrogen, 4-monomethoxytrityl group, 4,4'-dimethoxytrityl group or 4,4 ', 4 "-trimethoxytrityl group.
- a twelfth aspect of the present invention provides a solid support in which polyethylene glycol is bonded, wherein the solid support is controlled pore glass (CPG).
- CPG controlled pore glass
- a thirteenth aspect of the present invention provides a solid support in which the CPG is bonded polyethylene glycol having a diameter of 40 to 180 ⁇ m and a pore size of 500 ⁇ to 3000 ⁇ m.
- a fourteenth aspect of the present invention provides a solid support bonded to polyethylene glycol, which is 3'-PEG-CPG, having the structure of Formula IV:
- R is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl or heteroaryl; n is an integer of 5 or more and 120 or less.
- a seventeenth aspect of the present invention provides a nanoparticle composed of the first or second siRNA conjugate.
- the nineteenth aspect of the present invention provides a method of treatment, wherein the nanoparticles are administered to the body by oral administration or intravenous injection.
- a twentieth aspect of the present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of the first or second siRNA conjugate.
- the twenty-first aspect of the present invention also provides a pharmaceutical composition comprising a pharmaceutically effective amount of the seventeenth nanoparticle.
- the present invention provides siRNA and polymer compound conjugates of the following structure:
- a and B are each independently a hydrophilic polymer or a hydrophobic polymer compound
- X, Y are each independently a simple covalent bond or a linker-mediated covalent bond
- R represents siRNA.
- the present invention also provides a siRNA and a polymer compound conjugate having the structure:
- A is a hydrophobic polymer compound
- X is a simple covalent bond or a linker mediated covalent bond
- R represents siRNA
- the oligo strand of the siRNA preferably comprises 19 to 31 nucleotides.
- the siRNA usable in the present invention may employ siRNAs derived from any gene that is or may be used for gene therapy or research.
- the hydrophobic polymer compound is preferably a hydrophobic polymer compound having a molecular weight of 250 to 1,000.
- Examples of the hydrophobic polymer compound include saturated hydrocarbons, preferably C 16 to C 50 saturated hydrocarbons and cholesterol. At this time, the hydrophobic polymer compound is not limited to the saturated hydrocarbon and cholesterol.
- the hydrophobic polymer compound plays a role of causing a hydrophobic interaction to form a micelle composed of siRNA and a hydrophobic polymer compound conjugate.
- saturated hydrocarbons have the advantage of being easily conjugated in the preparation of siRNA, which is very suitable for the preparation of the conjugate of the present invention.
- the covalent bond (ie, X, Y) may be either a non-degradable bond or a degradable bond.
- the non-degradable bonds include amide bonds or phosphate bonds
- the degradable bonds include disulfide bonds, acid-decomposable bonds, ester bonds, anhydride bonds, biodegradable bonds, or enzyme-degradable bonds, but are not limited thereto. no.
- the linker that mediates the linkage covalently binds the end groups of the hydrophilic polymer (or hydrophobic polymer) and the residue derived from siRNA, and is not particularly limited as long as it provides a bond that can be degraded in a predetermined environment as necessary.
- the linker may include any compound that binds to activate siRNA and / or hydrophilic polymer (or hydrophobic polymer) during the preparation of the conjugate.
- the hydrophilic polymer compound is preferably a nonionic polymer compound having a molecular weight of 1,000 to 10,000.
- nonionic hydrophilic high molecular compounds such as polyethyleneglycol, polyvinylpyrrolidone, and polyoxazoline, as a hydrophilic high molecular compound, it is not necessarily limited to this.
- the functional group of the said hydrophilic high molecular compound may be substituted by another functional group as needed.
- PEG has a terminal capable of introducing various molecular weights and functional groups, and has good affinity in vivo, does not induce an immune response, and increases solubility in water to improve gene transfer efficiency in vivo. As it increases, it is very suitable for the preparation of the conjugates of the present invention.
- the present invention provides a solid support bonded to the polyethylene glycol of the following structure.
- solid supports include, but are not limited to, for example, CPG, polystyrene, silica gel, cellulose paper, and the like; R is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl or heteroaryl; m is an integer from 2 to 18, n is an integer from 5 to 120 (Molar mass 282 to 5300); X corresponds to 4-monomethoxytrityl group, 4,4'-dimethoxytrityl group or 4,4 ', 4 "-trimethoxytrityl group and is removed after treatment with acid to form hydrogen.
- Solid support is CPG
- the diameter is preferably 40 to 180 mu m, and preferably has a pore size of 500 mu to 3000 mu m.
- the present invention also provides a solid support bonded to polyethylene glycol, which is 3'-PEG-CPG, having the structure of Formula IV:
- the present invention also provides a process for preparing 3'-PEG-CPG of formula IV comprising the following steps:
- R is alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl or heteroaryl; n is an integer of 5 or more and 120 or less.
- the present invention provides a method for preparing a conjugate between siRNA and PEG using the solid support to which the polyethylene glycol is bound. Specifically,
- siRNA conjugate comprising covalently connecting the end group of the siRNA and polyethylene glycol. This allows for the efficient preparation of oligonucleotides including RNA, DNA, RNA-DNA chimeras and analogs.
- the siRNA can be prepared using a method of linking phosphodiester bonds forming an RNA backbone structure using ⁇ -cyanoethyl phosphoramidite ( ⁇ -cyanoethyl phosphoramidite) (Shina et al. Nucleic Acids Research, 12: 4539-4557, 1984).
- ⁇ -cyanoethyl phosphoramidite ⁇ -cyanoethyl phosphoramidite
- a reactant may be obtained, but is not limited thereto.
- the present invention also provides a nanoparticle consisting of the siRNA conjugate.
- the siRNA and the polymer compound conjugate of the present invention can form a nanoparticle structure by interaction, and the nanoparticles composed of the siRNA and the polymer compound conjugate and the siRNA polymer compound conjugate thus formed improve the intracellular delivery of the siRNA, which is a disease It is possible to apply the model for therapeutic purposes.
- the production of more specific conjugates and the characteristics, cell delivery efficiency and effects of the nanoparticles composed of the conjugates will be described in more detail in the following examples.
- the present invention also provides a gene therapy method using the nanoparticles.
- a gene therapy method comprising the step of preparing a nanoparticle consisting of the siRNA polymer compound conjugate and the step of injecting the nanoparticles into the body of the animal.
- the present invention also provides a pharmaceutical composition comprising a pharmaceutically effective amount of nanoparticles composed of the siRNA conjugates.
- composition of the present invention may be prepared by containing one or more pharmaceutically acceptable carriers in addition to the active ingredients described above for administration.
- Pharmaceutically acceptable carriers should be compatible with the active ingredients of the present invention and may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components. If necessary, antioxidants, ona sap solution, bacteriostatic agents, and the like can be added.
- diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like.
- it may be preferably formulated according to each disease or component by an appropriate method in the art or using a method disclosed in Remington's pharmaceutical Science (Mack Publishing company, Easton PA).
- the pharmaceutical composition of the present invention can be determined by one of ordinary skill in the art based on the symptoms and severity of the disease of a typical patient. It may also be formulated in various forms, such as powders, tablets, capsules, solutions, injections, ointments, syrups, etc., and may also be provided in unit-dose or multi-dose containers, such as sealed ampoules and bottles.
- the pharmaceutical composition of the present invention can be administered orally or parenterally.
- Routes of administration of the pharmaceutical compositions according to the invention are not limited to, for example, oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intestinal Sublingual, or topical administration is possible.
- the pharmaceutical compositions of the present invention can be formulated into suitable formulations using known techniques.
- the dosage of the composition of the present invention varies in the range depending on the weight, age, sex, health condition, diet, time of administration, method, excretion rate and severity of the disease, etc. of the patient, and easily available to those skilled in the art. You can decide.
- the nanoparticles composed of the siRNA polymer compound conjugates of the present invention can efficiently deliver therapeutic siRNA into cells by improving the in vivo stability of siRNA, and the activity of siRNA at relatively low concentrations without transfection material As well as a tool for siRNA treatment for cancer and other infectious diseases, the new type of siRNA delivery system can be very useful in basic research and medical industry for biotechnology.
- 1 is a structural formula of the prepared 3'-PEG-CPG.
- FIG. 3 is 1 H NMR data of [Compound A], which is a 3′-PEG reagent for binding to LCAA-CPG in Example 1.
- FIG. 3 is 1 H NMR data of [Compound A], which is a 3′-PEG reagent for binding to LCAA-CPG in Example 1.
- FIG. 5 is 1 H NMR data of [Compound C], which is a 3′-PEG reagent for binding with LCAA-CPG in Example 1.
- FIG. 5 is 1 H NMR data of [Compound C], which is a 3′-PEG reagent for binding with LCAA-CPG in Example 1.
- Example 6 is Maldi-Tof molecular weight data after 3′-PEG-CPG and oligonucleotide (siRNA) preparation in Example 1-3.
- siRNA means naked siRNA, each conjugate representing an siRNA polymer compound conjugate shown in Table 1.
- 19, 23, 27, 31mer refers to siRNA consisting of 19, 23, 27, 31 nucleotides, respectively, all prepared siRNA polymer compound conjugate in the structure of siRNA conjugate 4.
- Figure 9 shows the degradation of siRNA with time in the presence of serum proteins for the evaluation of the stability in the blood of the siRNA polymer conjugate conjugated form of the siRNA and hydrophilic polymer compound conjugated without the polymer compound Electrophoresis picture showing.
- FIG. 10 is a schematic diagram of nanoparticles formed by a siRNA polymer compound complex.
- Figure 11 shows the size of the nanoparticles measured by zeta potential meter of naked siRNA nanoparticles to which the polymer compound is not conjugated.
- Figure 12 shows the size of the nanoparticles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 9.
- Figure 13 shows the size of the nanoparticles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 10.
- Figure 14 shows the size of the nanoparticles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 11.
- Figure 15 shows the size of the nanoparticles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 12.
- Figure 16 shows the size of the nanoparticles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 13.
- Figure 17 shows the mRNA of the survivin gene after transfection with a transfection material in order to analyze the RNAi effect of the siRNA polymer conjugate conjugated form of the siRNA and PEG hydrophilic polymer compound of the original form It is a graph comparing the degree of expression.
- Figure 18 is transfected with a transfection material to analyze the RNAi effect of the siRNA of the long sequence modified with the siRNA and siRNA polymer compound conjugate 4 structure of the original form, and compare the mRNA expression level of survivin gene One graph.
- Figure 19 shows the survivin gene after transfection under conditions without transfection material to analyze the RNAi effect of the siRNA polymer compound conjugates modified with siRNA and siRNA polymer compound conjugates 1 to 5 and 9 to 14 of the original form It is a graph comparing the degree of inhibition of mRNA expression.
- Example 1-1-2 500 mg (0.206 mmol) of Compound A obtained in Example 1-1-2 was dissolved in 10 ml of methylene chloride, and 83.14 ⁇ l (1.03 mmol) of pyridine was added thereto. To this, 165 mg (0.781 mmol) of N-succinimidyl trifluoro acetic acid (Sigma Aldrich, USA) was added thereto, and the reaction was terminated after stirring at room temperature for 7 hours.
- N-succinimidyl trifluoro acetic acid Sigma Aldrich, USA
- Example 1-2-2 Preparation of 3'-PEG-CPG (2000 ') using 2-succinic acid 2- [bis- (4-dimethoxytrityl) -poly (ethylene glycol)] [Compound A]
- Compound B was used to prepare 3'-PEG-CPG (2000 Hz).
- Example 1-2-1 Specifically LCAA-CPG (2000 Hz) obtained in Example 1-2-1 1 g was sufficiently wetted with 8 ml of pyridine.
- compound B A solution of 205 mg (2eq) and 55 ⁇ l of triethylamine in 2 ml of pyridine was evenly mixed with the LCAA-CPG solution. After the reaction was carried out at 50 to 60 ° C. for 8 hours, the reaction mixture was filtered and the filtered coupling-CPG was washed sequentially with methanol, water and methylene chloride, followed by vacuum drying. 10 ml of pyridine was added to 1 g of the dried coupling-CPG, and then wetted.
- Example 6 is a result of confirming the Maldi-Tof molecular weight after preparing the siRNA as shown in Example 2, using 3'-PEG-CPG as a starting material.
- LCAA-CPG (2000 Hz) obtained in Example 1-2-1 1 g was sufficiently wetted with 8 ml of pyridine.
- compound C A solution of 200 mg and 55 ⁇ l of triethylamine in 2 ml of pyridine was mixed with the LCAA-CPG solution. After reacting at 50 to 60 ° C. for 8 hours, the reaction mixture was filtered and the filtered coupling-CPG was washed with methanol, water and methylene chloride in that order and dried in vacuo. 10 ml of pyridine was added to 1 g of dried coupling-CPG, and then wetted.
- Example 7 shows the results of preparing siRNAs as shown in Example 2 below using 3′-PEG-CPG as a starting material.
- survivin siRNA was used to inhibit survivin.
- Survivin is a protein commonly expressed in most neoplastic tumors or transformed cell lines that have been tested so far, and is expected to be an important target for anticancer therapy (Abbrosini G. et al. Nat. Med. 3 ( 8): 917-921, 1997).
- the survivin siRNA sequence of the present invention when composed of 19 nucleotides, is composed of a sense strand described in SEQ ID NO: 1 and an antisense strand that is complementary thereto.
- the nucleotide sequence is set forth as SEQ ID NO: 2, 3, and 4.
- the siRNA was prepared using a method of linking phosphodiester bonds forming an RNA backbone structure using ⁇ -cyanoethyl phosphoramidite. Specifically, using a RNA synthesizer (384 Synthesizer, BIONEER, Korea), a series of processes including deblocking, binding, oxidation, and capping on a solid support to which nucleotides are attached is repeated to produce a reaction containing RNA of a desired length. Obtained.
- siRNA polymer conjugates were prepared by hexadecane (C16) or octadecane (C18) saturated hydrocarbons using PEG or a dodecane linker, a hydrophobic polymer compound, at the 5 'end.
- the reaction was performed using the 3'PEG-CPG prepared in Example 1 as a support, to prepare a siRNA polymer compound conjugate to which PEG is attached to the 3 'terminal.
- the reactants were separated by RNA using HPLC (LC-20A Prominence, SHIMADZU, Japan), and measured using a MALDI-TOF mass absorbance analyzer (MALDI TOF-MS, SHIMADZU, Japan) to measure molecular weight. It was confirmed that it matches the base sequence. Thereafter, the same amount of sense and antisense RNA strands were mixed and placed in 1X annealing buffer (30mM HEPES, 100mM Potassium acetate, 2mM Magnesium acetate, pH 7.0-7.5), reacted for 3 minutes in a 90 ° C constant temperature water bath, and then again at 37 ° C. To prepare the desired double-stranded siRNA polymer compound conjugates, respectively. The prepared siRNA polymer compound conjugate has the structure shown in Table 1. The prepared siRNA polymer compound conjugate was confirmed annealing through the electrophoresis picture (Fig. 8).
- siRNA polymer compound conjugates Conjugate name Conjugate structure name Terminal modification siRNA naked siRNA Sense: none Antisense: none siRNA polymer compound conjugate 1 5'PEG-sense siRNA Sense: 5'PEG Antisense: none siRNA polymer compound conjugate 2 5'PEG-antisense siRNA Sense: none Antisense: 5'PEG siRNA polymer compound conjugate 3 5'ssPEG-antisense siRNA Sense: none Antisense: 5'ssPEG siRNA polymer compound conjugate 4 5'PEG + PEG siRNA Sense: 5'PEG Antisense: 5'PEG siRNA polymer compound conjugate 5 5'PEG + ssPEG siRNA Sense: 5'PEG Antisense: 5'ssPEG siRNA polymer compound conjugate 6 3'PEG-sense siRNA Sense: 3'PEG Antisense: none siRNA polymer compound conjugate 7 3'PEG-antisense siRNA Sense
- siRNA polymer compound conjugate prepared and separated in Example 2 has improved stability compared to the original siRNA to which the polymer compound is not bound.
- the original unmodified siRNA and the siRNA polymer compound conjugates 1 to 5 prepared in Example 2 were added in a medium to which 10% FBS (fetal bovine serum) was added, which simulated in vivo conditions. After incubation for 6, 9, 12, 24, 36 or 48 hours, the degree of degradation of siRNA was examined by electrophoresis.
- FBS fetal bovine serum
- siRNA showed stability even up to 48 hours in the siRNA polymer compound conjugate in which PEG was introduced (FIG. 9).
- the siRNA showed stability up to 12 to 24 hours even at 10% serum conditions.
- siRNA polymer compound conjugates 9 to 14 hydrophobic interactions between hydrophobic polymer compounds imparted to the ends of siRNA form nanoparticles consisting of siRNA polymer compound conjugates, that is, micelles (FIG. 10). The size of the nanoparticles was measured by zeta-potential measurement.
- the nanoparticle sizes of the siRNA polymer compound conjugates 9 to 13 and siRNA prepared in Example 2 were measured.
- the size of the nanoparticles was homogenized (200 W, 40 kHz, 5 sec) using an ultrasonic disperser (Wiseclean, DAIHAN, Korea). Homogenized nanoparticles were sized with a Zeta Potentiometer (Nano-ZS, MALVERN, UK). The refractive index of the material was 1.454, the absorption index was 0.001, and the temperature of the solvent, water, was 25 ° C. And the resulting viscosity and refractive index were measured. One measurement consisted of a size measurement consisting of 20 repetitions, which were repeated three times.
- FIG. 11 is a result showing the size of the particle measured by the zeta potential meter of naked siRNA nanoparticles.
- FIG. 13 shows the size of particles measured through a zeta potential detector of nanoparticles composed of siRNA polymer compound conjugate 10.
- the nanoparticles composed of siRNA polymer compound conjugate 10 58.9% of the particles having a size of 5.61-10.1 nm (maximum of 8.72 nm) were obtained.
- Figure 14 is a result showing the size of the particles measured by the zeta potential meter of the nanoparticles consisting of siRNA polymer compound conjugate 11.
- the nanoparticles composed of siRNA polymer compound conjugate 11 it can be seen that the one having a size of 5.61-10.1 nm (maximum of 8.72 nm) occupies 45.6%.
- FIG. 15 shows the size of particles measured through a zeta potential detector of nanoparticles composed of siRNA polymer compound conjugate 12.
- 23.6% had a size of 4.85-5.61nm
- 23.5% had a size of 21.0-32.7nm
- 23.1% had a size of 68.1-78.8nm. Can be.
- FIG. 16 shows the results of nanoparticle sizes measured through a zeta potential meter of a nanoparticle composed of siRNA polymer compound conjugate 13.
- the nanoparticles consisting of siRNA polymer compound conjugate 13 it can be seen that the one having a size of 4.85-8.72 nm (5.61 nm peak) occupies 84.6%.
- the size of the nanoparticles composed of siRNA polymer compound conjugates 9 to 13 had sizes of 4-8 nm except siRNA conjugate 12.
- the size of the nanoparticles was measured variously, which is thought to be due to the aggregation of the nanoparticles over time even when homogenized through an ultrasonic disperser during the measurement.
- the size of the nanoparticles composed of the measured siRNA conjugate shows a size of 100 nm or less, which is sufficient to be taken into the cell through pinocytosis (Kenneth A. Dawson et al. nature nanotechnology 4: 84-85, 2009).
- Each siRNA polymer compound conjugate 1 to 8 prepared in Example 2 was used to transfect human cervical cancer cell lines, which are tumor cell lines, and the expression patterns of survivin genes were analyzed in the transfected tumor cell lines.
- Hela Human cervical cancer cells obtained from the American Type Culture Collection (ATCC) were 10% (v / v) fetal calf serum, penicillin 100 units / ml, streptococci in RPMI 1640 culture medium (GIBCO, Invitorgen, USA). 100 ⁇ g / ml of mycin was added and incubated under conditions of 37 ° C., 5% (v / v) CO 2 .
- the siRNA polymer compound conjugates 1 to 8 of SEQ ID NO: 1 prepared in Example 2 were transfected with a human uterine cancer cell line (HeLa), a tumor cell line, and expression patterns of survivin in the transfected tumor cell line. was analyzed.
- Tumor cell line 1.3 ⁇ 10 5 cultured in Example 5-1 was incubated in RPMI 1640 for 18 hours in a 6-well plate at 37 ° C. and 5% (v / v) CO 2 , and then the medium was removed. 800 ⁇ l Opti-MEM medium (GIBCO, USA) was dispensed per well.
- cDNA was prepared by extracting total RNA from the cell line transfected in Example 5-2-1, mRNA amount of survivin gene was quantified by real-time PCR.
- Example 5-2-2-1 RNA Isolation and cDNA Preparation from Transfected Cells
- RNA extraction kit (AccuPrep Cell total RNA extraction kit, BIONEER, Korea) the total RNA is extracted from the cell line transfected in Example 5-2-1, the extracted RNA is RNA reverse transcriptase (AccuPower Using CycleScript RT Premix / dT 20, Bioneer, Korea), cDNA was prepared by the following method.
- Example 5-2-2-1 Using the cDNA prepared in Example 5-2-2-1 as a template, the relative amount of survivin mRNA was quantified by real-time PCR in the following manner.
- HK gene a housekeeping gene
- HMBS Hydroxymethyl-bilane synthase
- HPRT1 Hydroxanthine phosphoribosyl-transferase1
- UBC Ubiquitin C
- YWHAZ Tyrosine 3-monooxygenase
- zeta polypeptide tryptophan 5-monooxygenase activtion protein
- the obtained Ct (threshold cycle) value of the survivin is calculated by calculating the normalized factor (NF) through the HK gene to obtain the corrected Ct value of the survivin. Differences in ⁇ Ct values were obtained using the experimental group treated only with the specification material as a control. MRNA expression rate of survivin was compared using the ⁇ Ct value and Formula 2 ( ⁇ Ct) ⁇ 100 (FIG. 17). mock means a control treated with only the transfection material.
- RNA- It is expected to reduce steric hindrance in complex formation with induced silencing complex (RISC).
- siRNA-PEG conjugates showed higher inhibition of target gene mRNA expression at low concentrations (20 nM) compared to high concentrations (100 nM), suggesting that PEG inhibits binding of siRNA to RISC at higher concentrations. do.
- Example 5-3 Inhibition of expression of target gene using long sequence siRNA polymer compound conjugate
- siRNA hydrophilic polymer compound conjugate together with the transfection material by using siRNA which induces terminal modification of the siRNA polymer compound conjugate 4 structure in the nucleotide sequence of siRNA SEQ ID NOs: 1-4 Expression inhibition was analyzed.
- Example 5-3-1 Transfection of Tumor Cell Lines Using siRNA Polymer Compound Conjugates
- Tumor cell line 1.3 ⁇ 10 5 cultured in Example 5-1 was incubated in RPMI 1640 for 24 hours in a condition 6-well plate at 37 ° C., 5% (v / v) CO 2 , and then the medium was removed. 800 ⁇ l Opti-MEM medium was dispensed per well.
- cDNA was prepared by extracting total RNA from the cell line transfected in Example 5-3-1, the mRNA amount of survivin gene was quantified by real-time PCR.
- RNA extraction kit (AccuPrep Cell total RNA extraction kit, BIONEER, Korea) the total RNA is extracted from the cell line transfected in Example 5-3-1, the extracted RNA is RNA reverse transcriptase (AccuPower Using CycleScript RT Premix / dT 20, Bioneer, Korea), cDNA was prepared by the following method.
- Example 5-3-2-1 Using the cDNA prepared in Example 5-3-2-1 as a template, the relative amount of survivin mRNA was quantified by real-time PCR in the following manner.
- the obtained Ct (threshold cycle) value of the survivin was calculated by calculating the normalized factor (NF) through the HK gene to obtain the corrected Ct value of the survivin. Differences in ⁇ Ct values were obtained using the experimental group treated only with the specification material as a control. MRNA expression rate of survivin was compared using the ⁇ Ct value and the formula 2 ( ⁇ Ct) ⁇ 100 (FIG. 18).
- 5'P + P represents the structure of the siRNA polymer compound conjugate 4, and treated under the conditions of 20nM, 100nM and compared the degree of inhibition of expression of the target gene.
- the long-chain naked siRNA when the long-chain naked siRNA was transformed into the siRNA polymer compound conjugate 4, the long-chain naked siRNA did not show a difference in expression inhibition effect of the target gene mRNA compared to the original naked siRNA.
- the siRNA was modified, it was found that the steric hindrance caused by PEG was reduced compared to the short chain. That is, in the case of long-chain siRNA, siRNA is cleaved into 19 + 2 structure by dicer in the mechanism of action of RNAi, and the cleaved siRNA binds to the RISC complex, resulting in RNAi mechanism of action.
- siRNA without PEG is present compared to SEQ ID NO: 1, and thus has relatively high interaction with RISC complex, from which RNAi induction effect is maintained. Seems to be.
- Each siRNA polymer compound conjugates 1 to 14 prepared in Example 2 were transfected with a human uterine cancer cell line (HeLa), which is a tumor cell line, and analyzed for expression of survivin in the transfected tumor cell line. It was.
- HeLa human uterine cancer cell line
- Hela Human cervical cancer cells obtained from the American Type Culture Collection (ATCC) were 10% (v / v) fetal calf serum, penicillin 100 units / ml, streptococci in RPMI 1640 culture medium (GIBCO / Invitorgen, USA). 100 ⁇ g / ml of mycin was added and incubated under conditions of 37 ° C., 5% (v / v) CO 2 .
- Tumor cell line 1.3 ⁇ 10 5 cultured in Example 6-1 was incubated in RPMI 1640 for 24 hours in a 6-well plate at 37 ° C. and 5% (v / v) CO 2 . 900 ⁇ l Opti-MEM medium was dispensed per well.
- Opti-MEM medium 100 ⁇ l of Opti-MEM medium and 5 or 10 ⁇ l of each of the siRNA polymer compound conjugates 9 to 14 (1 nmole / ⁇ l) prepared in Example 2 were added (final 500 nM, 1 ⁇ M treatment), followed by decomposition by high frequency sound.
- a solution was prepared by equalizing micelles composed of siRNA hydrophobic polymer compound conjugates through sonication.
- transfection solution 100 ⁇ l was dispensed into each well of Opti-MEM-dispersed tumor cell lines, followed by incubation for 24 hours, and then 1 ml of RPMI 1640 containing 20% FBS was added. It was further incubated for 24 hours under conditions of 37 ° C. and 5% (v / v) CO 2 , followed by incubation for a total of 48 hours after siRNA polymer compound complex treatment.
- mRNA amount of survivin gene was relatively quantified by real-time PCR.
- Example 6-3-1 RNA Isolation and cDNA Preparation from Transfected Cells
- RNA extraction kit (AccuPrep Cell total RNA extraction kit, BIONEER, Korea) the total RNA is extracted from the cell line transfected in Example 6-2, the extracted RNA is RNA reverse transcriptase (AccuPower Using CycleScript RT Premix / dT 20, Bioneer, Korea), cDNA was prepared by the following method.
- Example 6-3-1 Using the cDNA prepared in Example 6-3-1 as a template, the relative amount of survivin mRNA was quantified by real-time PCR in the following manner.
- HK gene a housekeeping gene (HK gene), HMBS (Hydroxymethyl-bilane synthase), HPRT1 (Hypoxanthine phosphoribosyl-transferase1), UBC (Ubiquitin C), and YWHAZ (Tyrosine 3-monooxygenase) / tryptophan 5-monooxygenase activtion protein (zeta polypeptide) as a standard gene, diluting the cDNA prepared in Example 6-3-1 by 1/5 and diluting cDNA 2 in each well of a 96-well plate and 2 10 ⁇ l of GreenStar TM PCR master mix (BIONEER, Korea), 6 ⁇ l of distilled water, and 1 ⁇ l of each HK gene qPCR primer (10 pmole / ⁇ l, respectively, BIONEER, Korea) were prepared for HK gene real-time PCR mixture.
- the 96-well plate containing the mixed solution was subjecte
- siRNA polymer compound conjugates 1 to 5 showed a high RNAi effect compared to high concentrations at low concentrations (500 nM).
- siRNA hydrophobic polymer compound conjugates of the conjugates 9 to 14 generally showed a low inhibition of survivin mRNA expression when treated at the same concentration (500 nM) as compared to the siRNA hydrophilic polymer compound conjugates 2 to 5.
- siRNA polymer compound conjugate 14 when treated in a high concentration (1 ⁇ M) conditions, especially in the siRNA polymer compound conjugate 14 showed a high survivin mRNA expression inhibitory effect.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Polyethers (AREA)
Abstract
Description
접합체명 | 접합체 구조명 | 말단 변형 형태 |
siRNA | naked siRNA | Sense: none |
Antisense: none | ||
siRNA 고분자 화합물 접합체 1 | 5'PEG-sense siRNA | Sense: 5'PEG |
Antisense: none | ||
siRNA 고분자 화합물 접합체 2 | 5'PEG-antisense siRNA | Sense: none |
Antisense: 5'PEG | ||
siRNA 고분자 화합물 접합체 3 | 5'ssPEG-antisense siRNA | Sense: none |
Antisense: 5'ssPEG | ||
siRNA 고분자 화합물 접합체 4 | 5'PEG+PEG siRNA | Sense: 5'PEG |
Antisense: 5'PEG | ||
siRNA 고분자 화합물 접합체 5 | 5'PEG+ssPEG siRNA | Sense: 5'PEG |
Antisense: 5'ssPEG | ||
siRNA 고분자 화합물 접합체 6 | 3'PEG-sense siRNA | Sense: 3'PEG |
Antisense: none | ||
siRNA 고분자 화합물 접합체 7 | 3'PEG-antisense siRNA | Sense: none |
Antisense: 3'PEG | ||
siRNA 고분자 화합물 접합체 8 | 3'PEG+PEG siRNA | Sense: 3'PEG |
Antisense: 3'PEG | ||
siRNA 고분자 화합물 접합체 9 | 5'C18-sense siRNA | Sense: 5'C18-C6-ss-C6 |
Antisense: none | ||
siRNA 고분자 화합물 접합체 10 | 5'C18+PEG siRNA | Sense: 5'C18-C6-ss-C6 |
Antisense: 5'PEG | ||
siRNA 고분자 화합물 접합체 11 | 5'C16+PEG siRNA | Sense: 5'C16-C6-ss-C6 |
Antisense: 5'PEG | ||
siRNA 고분자 화합물 접합체 12 | 5'C18-antisense siRNA | Sense: none |
Antisense: 5'C18-C6-ss-C6 | ||
siRNA 고분자 화합물 접합체 13 | 5'PEG+C18 siRNA | Sense: 5'PEG |
Antisense: 5'C18-C6-ss-C6 | ||
siRNA 고분자 화합물 접합체 14 | 5'PEG+C16 siRNA | Sense: 5'PEG |
Antisense: 5'C16-C6-ss-C6 |
Claims (21)
- 하기 구조의 siRNA와 고분자 화합물 접합체:A-X-R-Y-B.(상기에서 A 및 B는 각각 독립적으로 친수성 고분자 또는 소수성 고분자 화합물, X, Y는 각각 독립적으로 단순 공유결합 또는 링커가 매개된 공유결합이며, R은 siRNA를 나타낸다.)
- 하기 구조의 siRNA와 고분자 화합물 접합체:A-X-R.(상기에서 A는 소수성 고분자 화합물이고, X는 단순 공유결합 또는 링커가 매개된 공유결합이며, R은 siRNA를 나타낸다.)
- 청구항 1 또는 청구항 2에 있어서,상기 siRNA(R)의 단일가닥은 19 내지 31 개의 뉴클레오티드로 구성되는 접합체.
- 청구항 1 또는 청구항 2에 있어서,상기 소수성 고분자 화합물(A)는 분자량 250 내지 1,000인 소수성 고분자 화합물인 것을 특징으로 하는 접합체.
- 청구항 4에 있어서,상기 소수성 고분자 화합물(A)는 C16-C50의 포화탄화수소 또는 콜레스테롤인 접합체.
- 청구항 1 또는 청구항 2에 있어서,상기 공유결합(X,Y)은 비분해성 결합 또는 분해성 결합인 접합체.
- 청구항 6에 있어서,상기 비분해성 결합은 아미드 결합 또는 포스페이트 결합인 접합체.
- 청구항 6에 있어서,상기 분해성 결합은 이황화 결합, 산분해성 결합, 에스테르 결합, 안하이드라이드 결합, 생분해성 결합 및 효소 분해성 결합 중에서 선택되는 접합체.
- 청구항 1에 있어서,상기 친수성 고분자 화합물(A 또는 B)는 분자량 1,000 내지 10,000인 비이온성 고분자 화합물인 접합체.
- 청구항 9에 있어서,상기 친수성 고분자 화합물은 폴리에틸렌글리콜, 폴리비닐피롤리돈 및 폴리옥사졸린으로 구성된 군으로부터 선택되는 접합체.
- 청구항 11에 있어서,상기 고형 지지체가 CPG인 폴리에틸렌글리콜이 결합된 고형 지지체.
- 청구항 12에 있어서,상기 CPG는 직경이 40∼180 ㎛이고, 공극 크기가 500Å∼3000Å인 폴리에틸렌글리콜이 결합된 고형 지지체.
- 1) CPG에 3-아미노프로필트리에톡시실란을 반응시켜 LCAA-CPG를 형성하는 단계;2) 폴리에틸렌글리콜에 4,4'-디메톡시트리틸클로라이드를 반응시켜 2-[비스-(4-디메톡시트리틸)-폴리(에틸렌글리콜)]을 형성하는 단계;3) 상기 2)에서 형성된 화합물과 하기 화학식 1의 화합물을 반응시켜 하기 구조식 Ⅰ의 화합물을 형성하는 단계;4) 상기 형성된 하기 구조식 Ⅰ의 화합물과 4-니트로페닐클로로포르메이트를 반응시켜 하기 구조식 Ⅱ의 화합물을 형성하는 단계;5) 상기 3)에서 형성된 하기 구조식 Ⅰ의 화합물과 N-숙신이미딜트리플루오로아세트산를 반응시켜 하기 구조식 Ⅲ의 화합물을 형성하는 단계;6) 상기 1)에서 형성된 LCAA-CPG 화합물을 상기 3) 내지 5)에서 각각 형성된 하기 구조식 Ⅰ,Ⅱ 또는 Ⅲ의 화합물과 각각 반응시키는 단계를 포함하는 하기 구조식 Ⅳ 3'-PEG-CPG의 제조방법:[화학식 1][구조식 Ⅰ][구조식 Ⅱ][구조식 Ⅲ][구조식 Ⅳ][상기에서, R은 알킬, 알케닐, 알키닐, 아릴, 아릴알킬, 헤테로알킬 또는 헤테로아릴이며; n은 5 이상 120 이하의 정수이다.]
- 1) 청구항 11에 기재된 폴리에틸렌글리콜이 결합된 고형 지지체를 이용하여 표적 유전자에 대한 siRNA를 제조하는 단계;2) siRNA의 말단기와 폴리에틸렌글리콜을 공유결합으로 연결하는 단계를 포함하는 청구항 1 또는 청구항 2의 siRNA 접합체의 제조방법.
- 청구항 1 또는 청구항 2에 기재된 siRNA 접합체로 구성된 나노입자.
- 1) 청구항 17에 기재된 나노입자를 준비하는 단계; 및2) 상기 나노입자를 동물의 체내로 투입하는 단계를 포함하는 유전자 치료방법.
- 청구항 18에 있어서,상기 나노입자는 경구투여 또는 정맥주사의 방법으로 체내에 투여되는 것을 특징으로 하는 치료방법.
- 청구항 1 또는 청구항 2에 기재된 siRNA 접합체의 약학적 유효량을 포함하는 약제학적 조성물.
- 청구항 17에 기재된 나노입자의 약학적 유효량을 포함하는 약제학적 조성물.
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011150787/10A RU2558258C2 (ru) | 2009-05-14 | 2010-05-13 | Конъюгат мирнк и способ его получения |
BRPI1012141A BRPI1012141B1 (pt) | 2009-05-14 | 2010-05-13 | conjugado de sirna e método de preparação do mesmo |
CA2761749A CA2761749C (en) | 2009-05-14 | 2010-05-13 | Sirna conjugate and preparation method thereof |
AU2010248239A AU2010248239B2 (en) | 2009-05-14 | 2010-05-13 | siRNA conjugate and preparation method thereof |
CN201080021324.3A CN102439148B (zh) | 2009-05-14 | 2010-05-13 | siRNA缀合物及其制备方法 |
US13/319,885 US8779114B2 (en) | 2009-05-14 | 2010-05-13 | siRNA conjugate and preparation method thereof |
EP10775118.2A EP2463371B1 (en) | 2009-05-14 | 2010-05-13 | Sirna conjugate and preparation method thereof |
JP2012510752A JP5758381B2 (ja) | 2009-05-14 | 2010-05-13 | siRNA接合体及びその製造方法 |
US13/613,071 US8772472B2 (en) | 2009-05-14 | 2012-09-13 | SiRNA conjugate and preparation method thereof |
US14/291,540 US9211343B2 (en) | 2009-05-14 | 2014-05-30 | siRNA conjugate and preparation method thereof |
US14/291,656 US20140350233A1 (en) | 2009-05-14 | 2014-05-30 | Sirna conjugate and preparation method thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090042297A KR101224828B1 (ko) | 2009-05-14 | 2009-05-14 | siRNA 접합체 및 그 제조방법 |
KR10-2009-0042297 | 2009-05-14 |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/319,885 A-371-Of-International US8779114B2 (en) | 2009-05-14 | 2010-05-13 | siRNA conjugate and preparation method thereof |
US13/613,071 Division US8772472B2 (en) | 2009-05-14 | 2012-09-13 | SiRNA conjugate and preparation method thereof |
US14/291,656 Division US20140350233A1 (en) | 2009-05-14 | 2014-05-30 | Sirna conjugate and preparation method thereof |
US14/291,540 Division US9211343B2 (en) | 2009-05-14 | 2014-05-30 | siRNA conjugate and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010131916A2 true WO2010131916A2 (ko) | 2010-11-18 |
WO2010131916A3 WO2010131916A3 (ko) | 2011-04-07 |
Family
ID=43085466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2010/003039 WO2010131916A2 (ko) | 2009-05-14 | 2010-05-13 | siRNA 접합체 및 그 제조방법 |
Country Status (10)
Country | Link |
---|---|
US (4) | US8779114B2 (ko) |
EP (3) | EP2626427A3 (ko) |
JP (3) | JP5758381B2 (ko) |
KR (1) | KR101224828B1 (ko) |
CN (3) | CN102888404B (ko) |
AU (1) | AU2010248239B2 (ko) |
BR (1) | BRPI1012141B1 (ko) |
CA (2) | CA2761749C (ko) |
RU (2) | RU2558258C2 (ko) |
WO (1) | WO2010131916A2 (ko) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130080727A (ko) * | 2012-01-05 | 2013-07-15 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
CN104114704A (zh) * | 2012-01-05 | 2014-10-22 | 株式会社百奥尼 | 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法 |
US20140371432A1 (en) * | 2011-12-15 | 2014-12-18 | Bioneer Corporation | Novel oligonucleotide conjugates and use thereof |
RU2656154C2 (ru) * | 2013-07-05 | 2018-05-31 | Байонир Корпорейшн | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
WO2013109057A1 (ko) * | 2012-01-18 | 2013-07-25 | (주)바이오니아 | 자성나노입자-samirna 복합체 및 그 제조방법 |
AU2013330344B2 (en) | 2012-09-17 | 2018-07-05 | W. R. Grace & Co.-Conn. | Chromatography media and devices |
BR112015007637A2 (pt) * | 2012-10-05 | 2017-08-08 | Bioneer Corp | oligo rna de dupla hélice específico para amfiregulina, estrutura de oligo rna de dupla hélice e composição para prevenir ou tratar doenças respiratórias contendo o mesmo |
EP2930180B1 (en) * | 2012-12-06 | 2021-11-10 | Kyowa Hakko Bio Co., Ltd. | Double-stranded ribonucleic acid for adjuvants |
MX2016000021A (es) * | 2013-07-05 | 2017-04-06 | Bioneer Corp | Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn. |
US10030243B2 (en) | 2013-07-05 | 2018-07-24 | Bioneer Corporation | Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same |
KR20150006742A (ko) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
KR20150006743A (ko) * | 2013-07-09 | 2015-01-19 | (주)바이오니아 | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 |
BR112016023004B1 (pt) | 2014-04-04 | 2023-12-05 | Bioneer Corporation | Sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma |
WO2015168383A1 (en) | 2014-05-02 | 2015-11-05 | W. R. Grace & Co.-Conn. | Functionalized support material and methods of making and using functionalized support material |
CA2974195A1 (en) | 2014-10-15 | 2016-04-21 | University Of Connecticut | Bio-reducible self-assembled liquid crystalline block copolymer for drug delivery |
BR112017026193B1 (pt) | 2015-06-05 | 2021-09-14 | W.R. Grace & Co-Conn | Adsorventes, método de produção dos adsorventes e uso dos adsorventes |
WO2016204515A1 (ko) * | 2015-06-15 | 2016-12-22 | (주)바이오니아 | STAT3 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체, 이를 포함하는 조성물 및 이의 용도 |
KR101861738B1 (ko) | 2016-08-24 | 2018-05-29 | (주)바이오니아 | 마이크로 rna를 포함하는 이중나선 올리고 rna 구조체 |
AU2018237139A1 (en) * | 2017-03-22 | 2019-10-17 | The Regents Of The University Of California | Modified oligonucleotides and therapeutic uses thereof |
KR102141124B1 (ko) * | 2018-01-30 | 2020-08-04 | (주)바이오니아 | 이중 가닥 miRNA를 포함하는 이중나선 올리고뉴클레오타이드 구조체 및 이의 용도 |
MX2020012652A (es) | 2018-05-25 | 2021-05-27 | Bioneer Corp | Oligonucleotido bicatenario especifico del gen de anfirregulina y composicion para prevenir y tratar enfermedades relacionadas con la fibrosis y enfermedades respiratorias, que comprende el mismo. |
KR102473989B1 (ko) * | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
CN113454223B (zh) | 2019-01-15 | 2024-09-13 | 柏业公司 | 靶向dkk1基因的双链寡核苷酸、包含其的构建体以及含有其的脱发预防或毛发生长组合物 |
KR20210063137A (ko) | 2019-11-22 | 2021-06-01 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
AU2021270895A1 (en) | 2020-05-14 | 2022-12-15 | Bioneer Corporation | Composition for preventing or treating obesity-related disease containing amphiregulin-specific double-stranded oligonucleotide structure |
KR102701681B1 (ko) | 2020-05-22 | 2024-09-09 | (주)바이오니아 | 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스감염증-19〔covid-19〕치료용 조성물 |
KR102272800B1 (ko) | 2020-06-30 | 2021-07-05 | 국방과학연구소 | 코로나바이러스 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스 감염증-19 예방 및 치료용 조성물 |
EP4299078A1 (en) | 2021-02-25 | 2024-01-03 | Bioneer Corporation | Composition for alleviating hair graying, promoting hair growth and/or preventing or alleviating hair loss, comprising double-stranded mirna as active ingredient |
CN117677402A (zh) | 2021-03-08 | 2024-03-08 | 柏业公司 | 用于使用超声雾化器施用用于预防或治疗包括covid-19的呼吸道病毒感染、由病毒感染引起的肺纤维化或呼吸道疾病的双链寡核苷酸结构的组合物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451463A (en) * | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
US5141813A (en) * | 1989-08-28 | 1992-08-25 | Clontech Laboratories, Inc. | Multifunctional controlled pore glass reagent for solid phase oligonucleotide synthesis |
RU2142015C1 (ru) * | 1991-09-06 | 1999-11-27 | Рисерч Дивелопмент Фаундейшн | Фрагмент днк, кодирующий белок гелонина, и способ его получения, вектор, обеспечивающий экспрессию белка гелонина, рекомбинантный штамм e.coli - продуцент белка гелонина |
US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
US6348583B1 (en) * | 1999-08-30 | 2002-02-19 | Bio-Rad Laboratories, Inc. | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
US7491805B2 (en) * | 2001-05-18 | 2009-02-17 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
EP2314691A3 (en) | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
WO2004087931A1 (en) | 2003-04-03 | 2004-10-14 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
US7851615B2 (en) * | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
JP4579911B2 (ja) * | 2003-06-03 | 2010-11-10 | アイシス・ファーマシューティカルズ・インコーポレイテッド | スルビビン発現の調節 |
KR101147147B1 (ko) * | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
WO2007021142A1 (en) | 2005-08-17 | 2007-02-22 | Bioneer Corporation | Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof |
CN101346393B (zh) | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
WO2008014979A2 (en) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
EP2025348A1 (en) * | 2007-08-13 | 2009-02-18 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Targeted block copolymer micelles |
EP2195428B1 (en) * | 2007-09-19 | 2013-12-11 | Applied Biosystems, LLC | SiRNA SEQUENCE-INDEPENDENT MODIFICATION FORMATS FOR REDUCING OFF-TARGET PHENOTYPIC EFFECTS IN RNAi, AND STABILIZED FORMS THEREOF |
TW200927177A (en) * | 2007-10-24 | 2009-07-01 | Nat Inst Of Advanced Ind Scien | Lipid-modified double-stranded RNA having potent RNA interference effect |
KR101224828B1 (ko) | 2009-05-14 | 2013-01-22 | (주)바이오니아 | siRNA 접합체 및 그 제조방법 |
-
2009
- 2009-05-14 KR KR1020090042297A patent/KR101224828B1/ko active IP Right Grant
-
2010
- 2010-05-13 CA CA2761749A patent/CA2761749C/en active Active
- 2010-05-13 CN CN201210301551.2A patent/CN102888404B/zh active Active
- 2010-05-13 CN CN201310147988.XA patent/CN103233003B/zh active Active
- 2010-05-13 US US13/319,885 patent/US8779114B2/en active Active
- 2010-05-13 JP JP2012510752A patent/JP5758381B2/ja active Active
- 2010-05-13 RU RU2011150787/10A patent/RU2558258C2/ru active
- 2010-05-13 CN CN201080021324.3A patent/CN102439148B/zh active Active
- 2010-05-13 EP EP13159602.5A patent/EP2626427A3/en not_active Withdrawn
- 2010-05-13 CA CA2871888A patent/CA2871888A1/en not_active Abandoned
- 2010-05-13 BR BRPI1012141A patent/BRPI1012141B1/pt active IP Right Grant
- 2010-05-13 WO PCT/KR2010/003039 patent/WO2010131916A2/ko active Application Filing
- 2010-05-13 EP EP10775118.2A patent/EP2463371B1/en active Active
- 2010-05-13 AU AU2010248239A patent/AU2010248239B2/en active Active
- 2010-05-13 EP EP13185358.2A patent/EP2682466B1/en active Active
-
2012
- 2012-09-13 US US13/613,071 patent/US8772472B2/en active Active
-
2013
- 2013-05-08 JP JP2013098798A patent/JP5797688B2/ja active Active
- 2013-11-21 RU RU2013151977/10A patent/RU2571218C2/ru active
-
2014
- 2014-05-30 US US14/291,540 patent/US9211343B2/en active Active
- 2014-05-30 US US14/291,656 patent/US20140350233A1/en not_active Abandoned
- 2014-12-02 JP JP2014244541A patent/JP2015107115A/ja active Pending
Non-Patent Citations (22)
Title |
---|
"Remington's pharmaceutical Science", MACK PUBLISHING COMPANY |
ABBROSINI G. ET AL., NAT. MED., vol. 3, no. 8, 1997, pages 917 - 921 |
AMARZGUIOUI M. ET AL., NUCLEIC ACID RES., vol. 31, 2003, pages 589 - 595 |
BRAASCH D. A. ET AL., BIOORG. MED. CHEM. LETT., vol. 14, 2003, pages 1139 - 1143 |
CHIU Y.L.; RANA T.M., RNA, vol. 9, 2003, pages 1034 - 1048 |
DANA J. GARY ET AL., JOURNAL OF CONTROLLED RELEASE, vol. 121, 2007, pages 64 - 73 |
DEJNEKA NS ET AL., MOL VIS., vol. 28, no. 14, 2008, pages 997 - 1005 |
ELBASHIR, S.M.; HARBORTH, J.; LENDECKEL, W.; YALCIN, A.; WEBER, K.; TUSCHL, T., NATURE, vol. 411, 2001, pages 494 - 498 |
ELBASHIR, S.M.; LENDECKEL, W.; TUSCHL, T., GENES & DEV., vol. 15, 2001, pages 188 - 200 |
ELBASHIR, S.M.; MARTINEZ, J.; PATKANIOWSKA, A.; LENDECKEL, W.; TUSCHL, T., EMBO J., vol. 20, 2001, pages 6877 - 6888 |
FIRE ET AL., NATURE, vol. 391, 1998, pages 806 - 811 |
KENNETH A. DAWSON ET AL., NATURE NANOTECHNOLOGY, vol. 4, 2009, pages 84 - 85 |
LEHRMAN S., NATURE, vol. 401, no. 6753, 1999, pages 517 - 518 |
NOVINA; SHARP, NATURE, vol. 430, 2004, pages 161 - 164 |
RANA, T.M., NAT. REV. MOL.CELL BIOL., vol. 8, 2007, pages 23 - 36 |
RYAN P. MILLION, NATURE REVIEWS DRUG DISCOVERY, vol. 7, 2008, pages 115 - 116 |
See also references of EP2463371A4 |
SHIGERU KAWAKAMI; MITSURU HASHIDA, DRUG METAB. PHARMACOKINET, vol. 22, no. 3, 2007, pages 142 - 151 |
SHIGERY KAWAKAMI; MITSURU HASHIDA, DRUG METAB. PARMACOKINET, vol. 22, no. 3, 2007, pages 142 - 151 |
SHINA ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 4539 - 4557 |
SOUTSCHEK J. ET AL., NATURE, vol. 432, 2004, pages 173 - 178 |
TOMARI, Y.; ZAMORE, P.D., GENES DEV., vol. 19, 2005, pages 517 - 529 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3733848A1 (en) * | 2011-12-15 | 2020-11-04 | Bioneer Corporation | Antisense oligonucleotide conjugates and use thereof |
US20140371432A1 (en) * | 2011-12-15 | 2014-12-18 | Bioneer Corporation | Novel oligonucleotide conjugates and use thereof |
CN104244987A (zh) * | 2011-12-15 | 2014-12-24 | 株式会社百奥尼 | 新型寡核苷酸缀合物及其应用 |
JP2015506919A (ja) * | 2011-12-15 | 2015-03-05 | バイオニア コーポレーションBioneer Corporation | 新規オリゴヌクレオチド接合体およびその用途 |
EP2796150A4 (en) * | 2011-12-15 | 2015-07-01 | Bioneer Corp | NOVEL OLIGONUCLEOTIDE CONJUGATES AND USE THEREOF |
JP2016216468A (ja) * | 2011-12-15 | 2016-12-22 | バイオニア コーポレーションBioneer Corporation | 新規オリゴヌクレオチド接合体およびその用途 |
CN104114704A (zh) * | 2012-01-05 | 2014-10-22 | 株式会社百奥尼 | 高效率的纳米颗粒型双螺旋寡rna结构体及其制备方法 |
KR101722948B1 (ko) * | 2012-01-05 | 2017-04-04 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
KR20130080727A (ko) * | 2012-01-05 | 2013-07-15 | (주)바이오니아 | 리간드가 결합된 이중나선 올리고 rna 구조체 및 그 제조방법 |
RU2656154C2 (ru) * | 2013-07-05 | 2018-05-31 | Байонир Корпорейшн | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010131916A2 (ko) | siRNA 접합체 및 그 제조방법 | |
WO2013089522A1 (ko) | 신규한 올리고뉴클레오티드 접합체 및 그 용도 | |
WO2015002511A1 (ko) | 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법 | |
WO2013103249A1 (ko) | 고효율 나노입자형 이중나선 올리고 rna 구조체 및 그의 제조방법 | |
WO2015002513A2 (ko) | 호흡기 질환 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 호흡기 질환 예방 또는 치료용 조성물 | |
WO2010090452A2 (ko) | 세포 내 전달능이 증가된 작은 간섭 rna 복합체 | |
WO2021145595A1 (ko) | 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도 | |
WO2015152693A2 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
WO2018030789A1 (ko) | 세포투과성이 향상된 펩티드 핵산 복합체 및 이를 포함하는 약학적 조성물 | |
WO2019225968A1 (ko) | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 | |
WO2015005669A1 (en) | LIVER CANCER RELATED GENES-SPECIFIC siRNA, DOUBLE-STRANDED OLIGO RNA MOLECULES COMPRISING THE siRNA, AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME | |
WO2019156366A1 (ko) | 핵산 복합체를 함유하는 피부 투과성 전달체 및 이의 용도 | |
WO2022139528A1 (ko) | 만노스를 포함하는 지질 나노입자 또는 이의 용도 | |
KR101241852B1 (ko) | siRNA 접합체 및 그 제조방법 | |
WO2023182756A1 (ko) | 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물 | |
WO2015002512A1 (ko) | 뎅기 바이러스 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 뎅기 바이러스 증식 억제용 조성물 | |
WO2014054927A1 (ko) | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 | |
WO2019022586A9 (ko) | 간암의 예방 또는 치료용 약학적 조성물 | |
WO2023136688A1 (ko) | 생분해성 이황화 결합을 포함하는 이온화 가능한 지질 및 이를 포함하는 지질나노입자 | |
WO2023043220A1 (ko) | Wfdc2의 발현을 조절하는 안티센스 화합물 | |
KR101392973B1 (ko) | siRNA 접합체 및 그 제조방법 | |
WO2020111614A1 (ko) | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 | |
WO2022131398A1 (ko) | 유전자 발현 및 억제가 동시에 가능한 핵산 구조체 | |
WO2020027641A1 (ko) | 아토피성 질환 예방 또는 치료용 약학적 조성물 | |
WO2022225353A1 (ko) | 타겟 유전자 조절을 위한 다기능성 핵산 구조체 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080021324.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10775118 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2336/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012510752 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2761749 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010248239 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010775118 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010248239 Country of ref document: AU Date of ref document: 20100513 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2011150787 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13319885 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI1012141 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI1012141 Country of ref document: BR Kind code of ref document: A2 Effective date: 20111116 |